title: Effects of canrenone in patients with metabolic syndrome.
abstract: BACKGROUND
  Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults.
  
  
  OBJECTIVE
  The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome. A total of 145 patients were treated with placebo or canrenone, 50 mg/day, for 3 months and then 50 mg b.i.d. till the end of the study. Blood pressure, body weight, body mass index, fasting plasma glucose (FPG), fasting plasma insulin, HOMA-IR, lipid profile, plasma aldosterone, brain natriuretic peptide, high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α) and M value were evaluated.
  
  
  RESULTS
  A decrease of blood pressure was observed in canrenone group compared to baseline; moreover, systolic blood pressure value recorded after 6 months of canrenone therapy was lower than the one recorded with placebo. Canrenone gave a significant decrease of FPI and HOMA index, and an increase of M value both compared to baseline and to placebo. Canrenone also decreased triglycerides and FPG was not observed with placebo. Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-α compared to baseline and to placebo.
  
  
  CONCLUSIONS
  Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients.
authors.affiliation: University of Pavia, Department of Internal Medicine and Therapeutics, Fondazione IRCCS Policlinico S. Matteo , P.le C. Golgi, 2 - 27100 Pavia , Italy +39 0382 526217 ; +39 0382 526259 ; giuseppe.derosa@unipv.it.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Aldo
authors.initials: A
authors.lastname: Bonaventura
authors.forename: Lucio
authors.initials: L
authors.lastname: Bianchi
authors.forename: Davide
authors.initials: D
authors.lastname: Romano
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Elena
authors.initials: E
authors.lastname: Fogari
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
mesh_terms: D000368:Aged; D000450:Aldosterone / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D002192:Canrenone / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001786:Blood Glucose; D000451:Mineralocorticoid Receptor Antagonists; D014409:Tumor Necrosis Factor-alpha; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D002192:Canrenone; D002097:C-Reactive Protein